Entero Therapeutics (ENTO) Competitors $0.55 -0.02 (-3.40%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. BCLI, ADXN, CTXR, SNSE, BTAI, SLXN, ACXP, TSBX, BMRA, and PRTGShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Brainstorm Cell Therapeutics (BCLI), Addex Therapeutics (ADXN), Citius Pharmaceuticals (CTXR), Sensei Biotherapeutics (SNSE), BioXcel Therapeutics (BTAI), Silexion Therapeutics (SLXN), Acurx Pharmaceuticals (ACXP), Turnstone Biologics (TSBX), Biomerica (BMRA), and Portage Biotech (PRTG). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors Brainstorm Cell Therapeutics Addex Therapeutics Citius Pharmaceuticals Sensei Biotherapeutics BioXcel Therapeutics Silexion Therapeutics Acurx Pharmaceuticals Turnstone Biologics Biomerica Portage Biotech Entero Therapeutics (NASDAQ:ENTO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends. Does the media favor ENTO or BCLI? In the previous week, Entero Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 3 mentions for Entero Therapeutics and 2 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.44 beat Entero Therapeutics' score of 0.43 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Entero Therapeutics Neutral Brainstorm Cell Therapeutics Neutral Which has more volatility & risk, ENTO or BCLI? Entero Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Do analysts prefer ENTO or BCLI? Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 2,442.37%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, ENTO or BCLI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$15.80MN/AN/ABrainstorm Cell TherapeuticsN/AN/A-$17.19M-$3.36-0.35 Does the MarketBeat Community favor ENTO or BCLI? Brainstorm Cell Therapeutics received 291 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEntero TherapeuticsN/AN/ABrainstorm Cell TherapeuticsOutperform Votes29159.03% Underperform Votes20240.97% Do insiders & institutionals have more ownership in ENTO or BCLI? 12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 0.5% of Entero Therapeutics shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ENTO or BCLI more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -87.06% -12.01% Brainstorm Cell Therapeutics N/A N/A -528.56% SummaryBrainstorm Cell Therapeutics beats Entero Therapeutics on 8 of the 12 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.246.597.064.69Net Income-$15.80M$143.75M$3.23B$248.14M7 Day Performance11.99%3.72%2.67%2.39%1 Month Performance31.32%11.01%8.82%6.05%1 Year Performance-73.38%3.87%31.44%13.60% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.2311 of 5 stars$0.55-3.4%N/A-74.1%$2.63MN/A0.009News CoverageShort Interest ↑High Trading VolumeBCLIBrainstorm Cell Therapeutics4.0014 of 5 stars$1.08-2.7%$30.00+2,677.8%-81.1%$8.57MN/A-0.2340Short Interest ↑ADXNAddex Therapeutics2.5243 of 5 stars$8.08-0.1%$30.00+271.3%-1.2%$8.57M$404.10K-23.7630CTXRCitius Pharmaceuticals2.4298 of 5 stars$0.87+13.0%$54.50+6,164.4%-93.7%$8.55MN/A0.0020News CoverageAnalyst ForecastGap UpHigh Trading VolumeSNSESensei Biotherapeutics4.7494 of 5 stars$0.34+7.3%$4.50+1,231.0%-53.9%$8.52MN/A-0.2840Positive NewsShort Interest ↓BTAIBioXcel Therapeutics3.9041 of 5 stars$1.37+3.8%$42.60+3,009.5%-92.2%$8.30M$1.85M-0.0490Short Interest ↑SLXNSilexion TherapeuticsN/A$0.95-1.0%$5.00+426.0%N/A$8.26MN/A0.00N/AUpcoming EarningsACXPAcurx Pharmaceuticals3.2503 of 5 stars$0.35-7.7%$8.00+2,198.9%-86.3%$8.17MN/A-0.323Positive NewsHigh Trading VolumeTSBXTurnstone Biologics3.3047 of 5 stars$0.35+11.9%$0.45+28.6%-87.5%$8.10M$19.31M-0.1182Positive NewsShort Interest ↓Gap DownHigh Trading VolumeBMRABiomerica0.335 of 5 stars$3.18-6.2%N/A-26.1%$8.10M$5.68M-9.3560Positive NewsShort Interest ↑PRTGPortage Biotech1.1029 of 5 stars$7.71-0.1%N/A+29.7%$8.09MN/A-0.196Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies Brainstorm Cell Therapeutics Competitors Addex Therapeutics Competitors Citius Pharmaceuticals Competitors Sensei Biotherapeutics Competitors BioXcel Therapeutics Competitors Silexion Therapeutics Competitors Acurx Pharmaceuticals Competitors Turnstone Biologics Competitors Biomerica Competitors Portage Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
